Meta's stock has been too penalized, says LightShed Partners' Rich Greenfield

Meta’s stock has been too penalized, says LightShed Partners’ Rich Greenfield

Rich Greenfield, LightShed Partners co-founder, joins CNBC’s ‘Squawk Box’ to break down the latest earnings report from Facebook’s parent company Meta.

Read More »
Caterpillar reports Q1 earnings, beats revenue and EPS estimates

Caterpillar reports Q1 earnings, beats revenue and EPS estimates

CNBC’s ‘Squawk Box’ team breaks down shares of Caterpillar following the company’s first-quarter earnings report.

Read More »
McGhee: It's hard being an investor right now, managing expectations around volatility

McGhee: It’s hard being an investor right now, managing expectations around volatility

Tiffany McGhee of Pivotal Advisors discusses whether positive results from some big tech names can offer a glimmer of hope, and highlights one company that plays a huge role in the global food supply chain.

Read More »
Archegos founder Bill Hwang, CFO charged in stock market fraud

Archegos founder Bill Hwang, CFO charged in stock market fraud

Archegos founder Bill Hwang is free on bail after being formally charged over accusations of a massive stock market fraud.

Read More »
Merck Q1 earnings beat Wall Street's estimates, raises full-year guidance

Merck Q1 earnings beat Wall Street’s estimates, raises full-year guidance

CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the latest first-quarter earnings report from drugmaker Merck, which beat Wall Street’s estimates on the top and bottom lines.

Read More »
We still like some Big Tech stocks, depends on investment horizon, says Nancy Tengler

We still like some Big Tech stocks, depends on investment horizon, says Nancy Tengler

Nancy Tengler, CEO and CIO at Laffer Tengler Investments, and Gunjan Banerji, markets reporter at the Wall Street Journal, join CNBC’s ‘Squawk Box’ to discuss tech stocks amid a busy week of earnings.

Read More »
Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial

Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial

A highly anticipated clinical trial from Eli Lilly showed its Type 2 diabetes drug met its primary endpoints. CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the results.

Read More »
Wedbush's Joel Kulina: Microsoft, Apple remain last safe havens of the market

Wedbush’s Joel Kulina: Microsoft, Apple remain last safe havens of the market

Joel Kulina, Head of Technology/Media Trading at Wedbush Securities, joins Worldwide Exchange to discuss the tech sector outlook ahead of the anticipated Big Tech earnings reports later today.

Read More »